SG Americas Securities LLC Buys Shares of 16,822 MacroGenics, Inc. (NASDAQ:MGNX)

SG Americas Securities LLC purchased a new position in shares of MacroGenics, Inc. (NASDAQ:MGNXFree Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 16,822 shares of the biopharmaceutical company’s stock, valued at approximately $55,000.

A number of other hedge funds have also modified their holdings of MGNX. Frazier Life Sciences Management L.P. lifted its position in MacroGenics by 21.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,010,727 shares of the biopharmaceutical company’s stock valued at $12,796,000 after buying an additional 539,023 shares during the last quarter. Susquehanna Fundamental Investments LLC lifted its holdings in shares of MacroGenics by 22.9% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 129,996 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 24,209 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of MacroGenics by 3,473.7% in the 2nd quarter. Millennium Management LLC now owns 3,312,672 shares of the biopharmaceutical company’s stock worth $14,079,000 after acquiring an additional 3,219,977 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of MacroGenics by 74.5% during the 2nd quarter. AQR Capital Management LLC now owns 143,161 shares of the biopharmaceutical company’s stock worth $608,000 after purchasing an additional 61,131 shares during the period. Finally, Armistice Capital LLC increased its holdings in MacroGenics by 150.0% in the 2nd quarter. Armistice Capital LLC now owns 6,000,000 shares of the biopharmaceutical company’s stock valued at $25,500,000 after purchasing an additional 3,600,000 shares during the last quarter. 96.89% of the stock is currently owned by hedge funds and other institutional investors.

MacroGenics Trading Up 0.9 %

MacroGenics stock opened at $3.52 on Tuesday. The company has a fifty day simple moving average of $3.54 and a 200-day simple moving average of $5.67. The stock has a market cap of $220.47 million, a P/E ratio of -9.03 and a beta of 2.08. MacroGenics, Inc. has a 12-month low of $2.95 and a 12-month high of $21.88.

MacroGenics (NASDAQ:MGNXGet Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.42). MacroGenics had a negative return on equity of 146.01% and a negative net margin of 332.47%. The business had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $24.14 million. As a group, sell-side analysts forecast that MacroGenics, Inc. will post -1.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on MGNX shares. Citigroup decreased their price target on MacroGenics from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. HC Wainwright restated a “neutral” rating and set a $4.00 target price on shares of MacroGenics in a report on Wednesday, September 18th. BMO Capital Markets dropped their target price on MacroGenics from $8.00 to $5.00 and set a “market perform” rating for the company in a research report on Wednesday, August 7th. StockNews.com raised shares of MacroGenics from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Evercore ISI upgraded shares of MacroGenics to a “strong-buy” rating in a report on Monday, September 16th. Eight research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, MacroGenics presently has a consensus rating of “Hold” and an average target price of $8.11.

View Our Latest Stock Report on MGNX

MacroGenics Profile

(Free Report)

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Featured Stories

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNXFree Report).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.